beta-lactams has been researched along with Community Acquired Infection in 221 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.45) | 18.2507 |
| 2000's | 99 (44.80) | 29.6817 |
| 2010's | 96 (43.44) | 24.3611 |
| 2020's | 25 (11.31) | 2.80 |
| Authors | Studies |
|---|---|
| Candel, FJ; González Del Castillo, J; Julián-Jiménez, A | 1 |
| Al-Salloum, J; Gillani, SW; Gulam, SM; Mahmood, RK | 1 |
| Alvarez, CA; Anzueto, A; Metersky, M; Mohammed, T; Mortensen, EM; Uddin, M | 1 |
| Chambers, HF; Creech, CB; Evans, S; Fowler, VG; Gerber, JS; Hofto, ME; Huskins, WC; Kong, Y; Kwon, J; Martin, JM; Newland, JG; Pettigrew, MM; Staat, MA; Wade, M; Walter, EB; Williams, DJ | 1 |
| Ismail, D | 1 |
| Chambers, HF; Creech, CB; Evans, S; Fowler, VG; Gent, JF; Gerber, JS; Hofto, ME; Huskins, WC; Kong, Y; Kwon, J; Martin, JM; Newland, JG; Pan, Q; Pettigrew, MM; Staat, MA; Wade, M; Walter, EB; Williams, DJ | 1 |
| Bridevaux, PO; Carballo, S; Chauffard, A; Garin, N; Prendki, V; Reny, JL; Stirnemann, J | 1 |
| Athlin, S; Hedlund, J; Magnuson, A; Nauclér, P; Spindler, C; Strålin, K | 1 |
| Jiao, Y; Ma, L; Peng, XX; Wang, CC; Xu, LY; Zhang, L; Zhao, CZ | 1 |
| Damås, JK; Heggelund, L; Tranung, M; Waagsbø, B | 1 |
| Bae, S; Chang, HH; Hwang, S; Jeon, Y; Kim, SW; Kim, Y; Kwon, KT; Lee, WK; Shim, EK; Shin, JH; Yang, KH | 1 |
| Karpova, OY; Pigusova, NA; Rachina, SA; Sinopalnikov, AI; Vasilyeva, IS | 1 |
| Arulkumaran, N; Cesar, A; Choi, SH; Saleem, N; Singer, M; Snow, TAC | 1 |
| Delamaire, F; Gacouin, A; Guillot, P; Lesouhaitier, M; Maamar, A; Painvin, B; Piau, C; Reizine, F; Tadié, JM | 1 |
| Greco Kinney, A; Hadique, S; Jain, P; Kovacic Scherrer, N; Sarkar, S; Wen, S | 1 |
| Bae, S; Baek, AR; Baek, MS; Chang, Y; Cho, WH; Gil, HI; Hong, SB; Jeon, K; Kim, C; Kim, JH; Lee, HB; Lee, HK; Min, KH; Moon, JY; Oh, JY; Park, HK; Shin, B; Yoo, KH | 1 |
| Ahmed, N; Alamri, IA; Alfaraj, AH; Alissa, M; Almaghaslah, M; Almogbel, MS; Alotaibi, J; Alqahtani, SA; Engku Abd Rahman, ENS; Halawi, MY; Ibrahim, FA; Irekeola, AA; Rabaan, AA; Yean, CY; Zahari, NIN | 1 |
| Fan, H; Liu, S; Ma, Y; Tong, X; Wang, D | 1 |
| Ceccato, A; Gabarrus, A; Torres, A | 1 |
| Cao, X; Forstner, C; Kolditz, M; König, R; Oswald, M; Pletz, M; Rohde, G; Rupp, J; Welte, T; Witzenrath, M | 1 |
| Anzueto, A; Brozek, J; Cooley, LA; Crothers, K; Dean, NC; Fine, MJ; Flanders, SA; Griffin, MR; Long, AC; Metersky, ML; Metlay, JP; Musher, DM; Restrepo, MI; Waterer, GW; Whitney, CG | 1 |
| Clark, CM; Kiel, A; Mason, J; Mergenhagen, KA; Sellick, JA; Wattengel, BA; White, A | 1 |
| Adami, ME; Alexiou, N; Giamarellos-Bourboulis, EJ; Gogos, C; Halvatzis, S; Kosmas, V; Koutoukas, P; Kyprianou, A; Kyprianou, M; Kyriakoudi, A; Kyriazopoulou, E; Lada, M; Makina, A; Niederman, MS; Pavlaki, M; Sinapidis, D; Stefos, A; Velissaris, D | 1 |
| Ishida, T; Ito, A; Tachibana, H; Tokumasu, H; Washio, Y; Yamazaki, A | 1 |
| Davis, AM; Olson, G | 1 |
| Fujita, S; Furuichi, K; Hara, A; Ikeo, K; Iwata, Y; Kitajima, S; Matsushima, K; Minami, T; Miyagawa, T; Nakajima, T; Ogura, H; Sakai, N; Sakai, Y; Sakai-Takemori, Y; Sato, K; Satou, K; Senda, Y; Shichino, S; Shimizu, M; Toyama, T; Ueha, S; Wada, T; Yamaguchi, K; Yamamura, Y; Yoneda, I | 1 |
| Fredlund, H; Källman, J; Liljedahl Prytz, K; Magnuson, A; Prag, M; Sundqvist, M | 1 |
| Aegerter, P; Bedos, JP; Benhamou, D; Bouchand, F; Chinet, T; Claessens, YE; Crémieux, AC; Davido, B; de Lastours, V; Deconinck, L; Delcey, V; Diamantis, S; Dinh, A; Dombret, MC; Dumoulin, J; Duran, C; Grenet, J; Kahn, JE; Labarère, J; Lagrange, A; Makhloufi, S; Mathieu, E; Matt, M; Mellon, G; Pépin, M; Perronne, C; Renaud, B; Ropers, J; Rouveix, E; Senard, O; Vitrat, V | 1 |
| Irie, H; Ishida, T; Ito, A; Nakanishi, Y; Otake, T; Tachibana, H; Tokioka, F; Washio, Y; Yamazaki, A | 1 |
| Averjanovaitė, V; Cincilevičiūtė, G; Danila, E; Mereškevičienė, R; Pliatkienė, G; Zablockis, R | 1 |
| Fekete, T | 1 |
| Bonten, MJM; Oosterheert, JJ; Postma, DF; Schweitzer, VA; van Smeden, M; van Werkhoven, CH | 1 |
| Abraham, I; Al Mohajer, M; Aljabri, A; Alshehri, S; Eljaaly, K; Kalil, AC; Nix, DE | 1 |
| Adamzik, M; Asmussen, S; Karlik, J; Peters, J; Rahmel, T; Steinmann, J | 1 |
| Arnold, FW; Bordon, J; Cavallazzi, R; Feldman, C; Fernandez-Botran, R; Mattingly, WA; Metersky, ML; Peyrani, P; Ramirez, JA; Wiemken, TL | 1 |
| Klevišar, MN; Lusa, L; Pirš, M; Premru, MM; Strle, F; Stupica, D; Terzić, S | 1 |
| Bonten, MJM; Oosterheert, JJ; Postma, DF; van de Garde, EMW; van Werkhoven, CH | 1 |
| Baptista, JP; Froes, F; Gonçalves-Pereira, J; Paiva, JA; Pereira, JM; Ribeiro, O | 1 |
| Smith, MJ | 1 |
| Ampofo, K; Anderson, EJ; Arnold, SR; Bramley, AM; Edwards, KM; Grijalva, CG; Hicks, LA; Jain, S; McCullers, JA; Pavia, AT; Self, WH; Williams, DJ; Zhu, Y | 1 |
| Badal, R; Cao, B; Chen, S; Chu, Y; Duan, Q; Feng, X; Gui, B; Hu, B; Hu, Z; Huang, W; Kong, H; Liao, K; Luo, Y; Ni, Y; Shao, H; Su, J; Sun, Z; Wang, Y; Wu, A; Xu, Y; Yang, Q; Yu, Y; Zhang, H; Zhang, S | 1 |
| Waterer, G | 1 |
| Horowitz, HW | 1 |
| Cao, B; Chen, L; Cui, X; Han, X; Li, H; Li, L; Li, Y; Liu, B; Liu, M; Liu, X; Purdy, JE; Suo, L; Wang, G; Wang, J; Wang, L; Wang, Y; Xiao, Y; Xing, X; Xue, C; Yao, X; Yu, G; Yu, H; Zhang, C; Zhou, F; Zhu, X | 1 |
| Månsson, V; Resman, F; Riesbeck, K; Thegerström, J | 1 |
| Aktaş Samur, A; Bilge, U; Çelenk, B; Çilli, A; Havlucu, Y; Hazar, A; Kılıç, Ö; Kılınç, O; Şakar Coşkun, A; Sayıner, A; Taşbakan, S; Tokgöz, F; Waterer, GW | 1 |
| Bueno, L; Ceccato, A; Cilloniz, C; Ferrer, M; Gabarrus, A; Garcia-Vidal, C; Martin-Loeches, I; Niederman, MS; Ranzani, OT; Torres, A | 1 |
| Covvey, JR; Freedy, HR; Guarascio, AJ; Nemecek, BD; Wilson, L; Yassin, MH; Zimmerman, DE | 1 |
| Bonten, MJM; Oosterheert, JJ; Postma, DF; Spitoni, C; van Elden, LJR; van Werkhoven, CH | 1 |
| Bootsma, HJ; Cobbaert, CM; de Vries, JJC; Groeneveld, GH; Joosten, SA; Kuijper, EJ; van der Reyden, TJ; van Dissel, JT | 1 |
| Hatakeyama, S; Matsui, H; Morisawa, Y; Sasabuchi, Y; Sasahara, T; Suzuki, J; Yamada, T; Yasunaga, H | 1 |
| Bakici, MZ; Celik, C; Elaldi, N; Engin, A; Gozel, MG; Kolayli, F; Vahaboglu, H | 1 |
| Badal, RE; Cao, B; Chen, M; Chu, Y; Duan, Q; Feng, X; Gui, B; Hu, B; Hu, Y; Hu, Z; Huang, W; Kong, H; Liao, K; Lu, J; Ni, Y; Shao, H; Shen, D; Su, J; Sun, Z; Wang, H; Wang, Y; Wu, A; Xu, Y; Yang, Q; Ye, H; Yu, Y; Zhang, H; Zhang, S | 1 |
| Bandettini, R; Buffa, P; Castagnola, E; Caviglia, I; Ciucci, A; Ginocchio, F; Guida, E; Haupt, R; Loy, A; Masa, DL; Mattioli, G; Perotti, M; Pini Prato, A | 1 |
| Arnold, C; Bassetti, S; Piso, RJ | 1 |
| Kim, SY; Ko, KS; Rhee, JY; Shin, SY | 1 |
| Adrie, C; Azoulay, E; Darmon, M; Dinh-Xuan, AT; Garrouste-Orgeas, M; Jamali, S; Kallel, H; Planquette, B; Schwebel, C; Souweine, B; Timsit, JF; Vignoud, L; Zahar, JR | 1 |
| Daisy, P; Murugan, M; Rajapandiyan, K; Ranjitsingh, AJ; Shanthi, S; Vijayalakshmi, P | 1 |
| Cesnauskas, G; Horn, PT; Novikovs, N; Ramesh, MK; Solomkin, JS; Stefanova, P; Sutcliffe, JA; Walpole, SM | 1 |
| Li, B; Nie, W; Xiu, Q | 1 |
| Bonten, MJ; Oosterheert, JJ; Postma, DF; van Werkhoven, CH | 1 |
| John, KR; Kesavan, LM; Kumar, VA; Manoharan, A; Mathai, D; Paul, B; Sugumar, M | 1 |
| Gardella, N; Grenon, S; Gutkind, G; Mollerach, M; Ubeda, C; von Specht, MH | 1 |
| Carballo, S; Chuard, C; Eich, G; Garin, N; Genné, D; Harbarth, S; Hugli, O; Lamy, O; Nendaz, M; Perneger, T; Perrier, A; Petignat, PA; Rutschmann, O; Seravalli, L | 1 |
| Chang, FY; Chiu, CH; Lin, DY; Lin, HA; Lin, HC; Lin, JC; Wang, JX; Yang, YS; Yeh, KM | 1 |
| Cavanillas, R; Grau, S; Lozano, V; Nocea, G; Valladares, A; Xie, Y | 1 |
| Boersma, WG; Bonten, MJ; Compaijen, CJ; Hoepelman, AI; Kluytmans, JA; Oosterheert, JJ; Postma, DF; Prins, JM; Thijsen, SF; van der Wall, E; van Elden, LJ; van Werkhoven, CH | 1 |
| Burki, TK | 1 |
| Paul, M; Raz-Pasteur, A; Shasha, D | 1 |
| Emmet O'Brien, M; Martin-Loeches, I; Restrepo, MI | 1 |
| Ambroggio, L; Blosky, MA; Graf, TR; Macaluso, M; Metlay, JP; Shah, SS; Test, M | 1 |
| Chan, YL; Chang, SS; Hsu, SM; Lee, CC; Lee, MG; Lee, SH; Pang, L | 1 |
| Bakour, R; Bonnet, R; Hamidi, M; Messai, Y; Robin, F; Yahiaoui, M | 1 |
| Badal, RE; Cao, B; Chen, S; Chu, Y; Duan, Q; Feng, X; Gui, B; Hu, B; Hu, Z; Huang, W; Kong, H; Liao, K; Luo, Y; Ni, Y; Shao, H; Su, J; Sun, Z; Wang, Y; Wu, A; Xu, Y; Yang, Q; Yu, Y; Zhang, H; Zhang, S | 1 |
| Ellidokuz, H; Kılıç Soylar, Ö; Kılınç, O | 1 |
| Barbosa, FC; Pinto, VP; Rocha, FR | 1 |
| Beall, B; Kim, L; McGee, L; Tomczyk, S | 1 |
| Haranaga, S; Higa, F; Horita, N; Kaneko, T; Kohno, S; Miki, M; Miyashita, N; Namkoong, H; Otsuka, T; Takahashi, H; Yoshida, M | 1 |
| Ortega G, M; Reyes B, T; Saldías P, F | 1 |
| Bravo-Ferrer, JM; Gutiérrez-Urbón, JM; Llinares, P; Pita, S; Ramos-Merino, L; Seoane-Pillado, T; Sousa, D; Vázquez-Rodríguez, P | 1 |
| Cleaver, L; Jolly, A; Podoll, JD; Walls, S; Wang, W; Wang, X; Zhu, Y | 1 |
| Kim, HJ; Kim, YH; Lee, JH | 1 |
| Arnold, FW | 1 |
| Kaysin, A; Viera, AJ | 1 |
| Falagas, ME; Trigkidis, KK; Vardakas, KZ | 1 |
| Galanis, I; Granath, F; Hedlund, J; Naucler, P; Rhedin, S; Spindler, C; Ternhag, A | 1 |
| Bonten, MJ; Mangen, MJ; Oosterheert, JJ; Postma, DF; van Werkhoven, CH | 1 |
| Alp, E; Badal, R; Gulay, Z; Koksal, I; Korten, V; Lob, S; Mete, B; Mulazimoglu, L; Oguz, VA; Tabak, F; Unal, S; Yilmaz, G; Zarakolu, P | 1 |
| Fernández, L; Gómez-Rice, A; Lillo, M; Maseda, E; Ramasco, F; Villagrán, MJ | 1 |
| Gobernado, M; González-Esteban, J; Redondo, E; Sanz-Rodríguez, C; Torroba, L; Villanueva, R | 1 |
| Pascual, A; Rodríguez-Baño, J | 1 |
| Arguedas, A; Blumer, J; Botet, FA; Cespedes, J; Gesser, R; Snyder, T; Wang, J; West, J; Wimmer, W; Yogev, R | 1 |
| Hasegawa, Y; Imaizumi, K; Maruyama, E; Ogawa, M; Ohashi, T; Sato, S; Shindo, Y | 1 |
| Low, DE | 1 |
| Athanassa, Z; Falagas, ME; Grammatikos, A; Korbila, IP; Siempos, II; Vardakas, KZ | 1 |
| Ensor, VM; Evans, JT; Hawkey, PM; Jamal, W; Rotimi, VO | 1 |
| Lortholary, O; Martin, C; Nordmann, P; Plesiat, P; Potel, G; Zahar, JR | 1 |
| File, TM | 1 |
| Apfalter, P; Assadian, O; Bachhofner, N; Bauer, CC; Blacky, A; Daxboeck, F; Diab-Elschahawi, M; Stadler, M | 1 |
| Marre, R; Martus, P; Schnoor, M; Suttorp, N; Tessmer, A; Welte, T | 1 |
| Marco, JA; Naranjo, OR; Rodríguez de Castro, F; Violán, JS | 1 |
| Lynch, JP; Zhanel, GG | 1 |
| Basuino, L; Chambers, HF; Tattevin, P | 1 |
| Bejon, P; Bowler, IC; Walker, TM | 1 |
| Aguilar, L; Barberán, J; González-Comeche, J; González-Moreno, J; González-Pina, B; Granizo, JJ; Irurzun, J; López-Dupla, M; Marín, A; Murcia, JM | 1 |
| Dooley, M; Mason, P; Roarty, J; Wells, RD | 1 |
| Boersma, WG; van der Eerden, MM | 1 |
| Arnold, FW; Brock, GN; LaJoie, AS; Lopardo, G; Menéndez, R; Peyrani, P; Ramirez, JA; Rello, J; Rossi, P; Torres, A | 1 |
| Bindayna, KM; Botta, GA; Khanfar, HS; Senok, AC | 1 |
| Gómez del Valle, C; Matía, M; Pérez-Calvo, JI; Torralba, MÁ | 1 |
| Brown, NM; Carmichael, AJ; Cooke, FJ; Ganner, M; Gkrania-Klotsas, E; Howard, JC; Kearns, AM; Stone, M | 1 |
| Witte, W | 1 |
| Congeni, BL | 1 |
| Hwang, KP; Shen, YH; Tang, YF | 1 |
| Pilla, V; Qi, C; Reed, K; Yu, JH | 1 |
| Boëlle, PY; Guillemot, D; Mandel, J; Opatowski, L; Temime, L; Varon, E | 1 |
| Frei, CR; Restrepo, MI | 1 |
| An, MM; Cao, YB; Gao, PH; Jiang, YY; Shen, H; Zou, Z | 1 |
| Cantón, R; Coque, TM; del Campo, R; Martín, O; Morosini, MI; Rodríguez-Baños, M; Rodríguez-Domínguez, M; Valverde, A | 1 |
| Akata, F; Celik, AD; Eroglu, C; Kuloglu, F; Torol, S; Vahaboğlu, H; Yulugkural, Z | 1 |
| Andre, C; Arpin, C; Coulange, L; De Barbeyrac, B; Dubois, V; M'zali, F; Megraud, F; Quentin, C; Rogues, AM | 1 |
| Bai, L; Cao, B; Gonzalez, R; Guo, P; Liu, YM; Ren, LL; Song, SF; Wang, C; Wang, JW; Yin, YD; Zhang, JZ; Zhang, YY; Zhao, F | 1 |
| Chen, TL; Fung, CP; Huang, LJ; Jeng, YY; Lin, YT; Liu, CY; Wang, FD | 1 |
| Boutbaoucht, M; Laghla, B; Nejmi, H; Samkaoui, MA | 1 |
| Bayraktar, B; Dalgic, N; Dincer, E; Pelit, S; Sancar, M | 1 |
| Ewig, S; Hecker, H; Marre, R; Suttorp, N; Welte, T | 1 |
| Alvarez-Rivera, E; Castro-Orozco, R; De Arco, MM; Rambaut-Donado, CL; Villafañe-Ferrer, LM; Vitola-Heins, GV | 1 |
| Ansaloni, L; Catena, F; Coccolini, F; Di Saverio, S; Ercolani, G; Gazzotti, F; Lazzareschi, D; Pinna, AD | 1 |
| Beekmann, SE; Hersh, AL; Newland, JG; Polgreen, PM; Shah, SS; Shapiro, DJ | 1 |
| Lemonovich, TL; Watkins, RR | 1 |
| Germel, C; Haag, A; Söderquist, B | 1 |
| Bauer, TT; Ernen, C; Hauptmeier, BM; Hecht, J; Lepper, PM; Nüesch, E; Ott, SR; Pletz, MW; Welte, T | 1 |
| Carbonnelle, S; De Bel, A; Dediste, A; Glupczynski, Y; Huang, TD; Jacobs, F; Jordens, P; Lismond, A; Schatt, P; Tulkens, PM; Van Bambeke, F; Verhaegen, J; Verschuren, F | 1 |
| Charles, PG; Grayson, ML; Johnson, PD; Teh, B | 1 |
| Chalumeau, M; Cohen, JF; Gendrel, D; Lecarpentier, T; Leis, A; Raymond, J | 1 |
| Bitterman, H; Denekamp, Y; Kochavi, T; Vardi, M | 1 |
| Hsueh, PR | 1 |
| Ambroggio, L; Evans, AA; Newschaffer, CJ; Shah, SS; Tabb, LP; Taylor, JA | 1 |
| Higuchi, W; Hung, WC; Iwao, Y; Khokhlova, O; Takano, T; Teng, LJ; Yamamoto, T | 1 |
| Carmeli, Y; Chmelnitsky, I; Karfunkel, D; Kotlovsky, T; Navon-Venezia, S | 1 |
| Artigas, A; Díaz-Martín, A; Ferrer, R; Garnacho-Montero, J; Levy, MM; Lopez-Pueyo, MJ; Martín-Loeches, I; Martínez-González, ML; Ortiz-Leyba, C; Piacentini, E | 1 |
| Banerjee, R; Enthaler, N; Fernandez, MG; Graml, C; Greenwood-Quaintance, KE; Patel, R | 1 |
| Ala-Kokko, TI; Karhu, J; Ohtonen, P; Syrjälä, H | 1 |
| Mildvan, D; Ruhe, J | 1 |
| Ahmed, S; Hameed, A; Hasan, F; Shah, AA | 1 |
| Bartizal, KF; Hicks, PS; Motyl, M; Pelak, B; Woods, GL | 1 |
| Friedland, I; Majumdar, A; Mixson, LA; Motyl, M; Woods, GL | 1 |
| Cambronero-Hernandez, E; Carides, A; Isaacs, R; Oliveria, T; Rohlf, J; Simon, S; Vetter, N | 1 |
| Peña, C; Pujol, M | 1 |
| Gopal Rao, G; Mahankali Rao, CS; Starke, I | 1 |
| Appelbaum, PC; Browne, FA; Jacobs, MR; Peric, M | 1 |
| Odagiri, S; Shimada, J; Takahashi, H; Watanuki, Y | 1 |
| Sakata, H | 1 |
| Gesser, RM; McCarroll, K; Teppler, H; Woods, GL | 1 |
| Karpov, OI; Strekachev, AIu; Zaĭtsev, AA | 1 |
| Friedland, IR; Isaacs, RD; McCarroll, KA; Woods, GL | 1 |
| Holmberg, H; Sjöberg, L; Stralin, K | 1 |
| Amyes, SG | 1 |
| Bertrand, X; Lallemand-De-Conto, S; Talon, D; Thouverez, M | 1 |
| Hammond, ML | 1 |
| Wexler, HM | 1 |
| DiNubile, MJ; Majumdar, AK; Nix, DE | 1 |
| Goldstein, EJ; Snydman, DR | 1 |
| Carides, A; Friedland, I; Isaacs, R; Ortiz-Ruiz, G; Vetter, N; Woods, GL | 1 |
| Friedland, IR; Gesser, RM; Herman, G; Isaacs, R; Meibohm, A; Mistry, G; Teppler, H; Woods, GL | 1 |
| Brown, SD; Stratton, CW | 1 |
| DiNubile, MJ; Friedland, IR; McCarroll, KA; Woods, GL | 1 |
| Goldstein, EJ | 1 |
| Blain, H; Durant, R; Jeandel, C; Raschilas, F; Tigoulet, F | 1 |
| Brink, AJ; Feldman, C; Grolman, DC; Muckart, D; Pretorius, J; Richards, GA; Senekal, M; Sieling, W | 1 |
| Verheij, TJ; Woodhead, M | 1 |
| Arrol, B; Mills, GD; Oehley, MR | 1 |
| Garau, J | 1 |
| Campillos, P; Cebrián, L; Gonzalo-Jiménez, N; López-Lozano, JM; Rodríguez-Díaz, JC; Royo, G; Yagüe, A | 1 |
| Borner, K; Burkhardt, O; Derendorf, H; Drewelow, B; Majcher-Peszynska, J; Mundkowski, R; Welte, T | 1 |
| Granizo Martínez, JJ | 1 |
| Fritsche, TR; Jones, RN; Sader, HS | 2 |
| Daoud, Z; Doucet-Populaire, F; Hakimé, NI; Hamzé, M; Mangeney, N; Matta, H; Mokhbat, JE; Moubareck, C; Rohban, R; Sarkis, DK | 1 |
| Ibrahim, KH; Rennie, RP | 1 |
| Chapman, AL; Greig, JM; Innes, JA | 1 |
| Bodmann, KF | 1 |
| Arpin, C; Brochet, JP; Dubois, V; Dutilh, B; Fischer, I; Jullin, J; Larribet, G; Maugein, J; Quentin, C | 1 |
| Toltzis, P | 1 |
| Wasielewski, S | 1 |
| Mufson, MA; Stanek, RJ | 1 |
| Anzueto, A; Mortensen, EM; Pugh, J; Restrepo, MI | 1 |
| Calbo, E; Garau, J; Gómez, L; Quintana, S; Romaní, V; Vidal, CG; Vila, J; Xercavins, M | 1 |
| Appelbaum, PC | 1 |
| Loh, LC | 1 |
| Baquero, F; Cantón, R; Coque, TM; García-Castillo, M; Loza, E; Morosini, MI; Novais, A; Valverde, A | 1 |
| Brink, M; Hagberg, L | 1 |
| Marco, F; Marcos, A; Mensa, JM; Pinart, M; Piñer, R; Torres, A; Vallès, X | 1 |
| Kohlhammer, Y; Marre, R; Raspe, H; Schäfer, T; Suttorp, N; Welte, T | 1 |
| Halank, M; Höffken, G; Kolditz, M | 1 |
| Burkhardt, O; Derendorf, H; Welte, T | 1 |
| Almanasreh, N; Andreassen, S; Cauda, R; Frank, U; Gafter-Gvili, A; Goldberg, E; Leibovici, L; Nielsen, AD; Paul, M; Tacconelli, E | 1 |
| Arroyo, L; Obando, I; Sanchez-Tatay, D | 1 |
| Cremades Romero, MJ; Martínez Moragón, E; Martínez Tomas, R; Menéndez Villanueva, R; Reyes Calzada, S; Soler Cataluña, JJ | 1 |
| Fung, CP; Huang, SS; Lee, CW; Lee, N; Lee, SC; Shieh, WB; Siu, LK | 1 |
| Farrell, DJ; Sunakawa, K | 1 |
| Cosler, L; Gupta, R; Kwa, A; Lodise, TP; Smith, RP | 1 |
| Basoli, A; Chirletti, P; Cirino, E; D'Ovidio, NG; Doglietto, GB; Ecari, M; Giglio, D; Giulini, SM; Malizia, A; Petrovic, J; Taffurelli, M | 1 |
| Brown, SD; Critchley, IA; Janjic, N; Tillotson, GS; Traczewski, MM | 1 |
| Llor, C | 1 |
| Dembry, LM; Gupta, K; Macintyre, A; Vanasse, G | 1 |
| Alos, JI; Cacho, J; Cuadros, J; Gomez-Garces, JL; Orden, B; Tamayo, J | 1 |
| Apisarnthanarak, A; Dejsirilert, S; Kiratisin, P; Kitphati, R; Mundy, LM; Saifon, P | 1 |
| Barcelona, L; Marín, M; Stamboulian, D | 1 |
| Biedenbach, DJ; Fritsche, TR; Jones, RN | 1 |
| André, C; Arpin, C; Brochet, JP; Coulange, L; Dubois, V; Dupart, V; Dutilh, B; Fischer, I; Grobost, F; Jullin, J; Lagrange, I; Larribet, G; Noury, P; Quentin, C; Scavelli, A | 1 |
| Ramirez, JA | 1 |
| Abdel-Rahman, EM; Dixon, RA; Ismael, NA | 1 |
| Chevalier, A; Choutet, P; Garo, B; Germaud, P; Régnier, B; Vuittenez, F | 1 |
| Sidorenko, SV | 1 |
| Caballero-Lopez, J; Carides, A; Friedland, IR; Ortiz-Ruiz, G; Woods, GL | 1 |
| Adam, D | 1 |
| Dajani, AS | 1 |
| Lode, H | 1 |
| Auckenthaler, R | 1 |
48 review(s) available for beta-lactams and Community Acquired Infection
| Article | Year |
|---|---|
[Community-acquired pneumonia: selection of empirical treatment and sequential therapy. SARS-CoV-2 implications].
Topics: beta-Lactams; Community-Acquired Infections; COVID-19; Humans; Pneumonia; SARS-CoV-2 | 2021 |
Comparative efficacy of azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Clarithromycin; Community-Acquired Infections; Humans; Pneumonia, Bacterial | 2021 |
Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Fluoroquinolones; Humans; Network Meta-Analysis; Pneumonia | 2022 |
Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Fluoroquinolones; Humans; Macrolides; Pneumonia, Bacterial; Randomized Controlled Trials as Topic | 2023 |
A Review of the Resistance Mechanisms for
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Artificial Intelligence; beta-Lactams; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Macrolides; Pneumonia; Streptococcus pneumoniae | 2023 |
Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Fluoroquinolones; Humans; Macrolides; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Treatment Failure | 2017 |
Community-acquired CTX-M-15-type ESBL-producing Escherichia coli meningitis: a case report and literature review.
Topics: Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Blood; Cerebrospinal Fluid; Community-Acquired Infections; Escherichia coli; Feces; Humans; Male; Meningitis, Escherichia coli; Microbial Sensitivity Tests; Otitis Media with Effusion; Treatment Outcome | 2013 |
β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Humans; Macrolides; Odds Ratio; Pneumonia; Publication Bias; Treatment Outcome | 2014 |
Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Fluoroquinolones; Humans; Macrolides; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure; Treatment Outcome; Withholding Treatment | 2015 |
Update on the combination effect of macrolide antibiotics in community-acquired pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Host-Pathogen Interactions; Humans; Immunomodulation; Macrolides; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Severity of Illness Index | 2015 |
The Spread of CTX-M-Type Extended-Spectrum β-Lactamases in Brazil: A Systematic Review.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Brazil; Community-Acquired Infections; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Gene Expression; Gene Transfer, Horizontal; Hospitals; Humans; Incidence; Klebsiella Infections; Klebsiella pneumoniae; Molecular Epidemiology | 2016 |
Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.
Topics: beta-Lactams; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Humans; Pneumococcal Infections; Pneumococcal Vaccines; Prevalence; Streptococcus pneumoniae; United States; Vaccines, Conjugate | 2016 |
Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Synergism; Drug Therapy, Combination; Humans; Macrolides; Pneumonia, Bacterial; Severity of Illness Index; Treatment Outcome | 2016 |
Are new antibiotics better than beta-lactams for non-critical inpatients with community-acquired pneumonia?
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Costs; Drug Resistance, Bacterial; Humans; Inpatients; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Databases, Factual; Drug Therapy, Combination; Fluoroquinolones; Humans; Intensive Care Units; Length of Stay; Macrolides; Odds Ratio; Pneumonia; Risk; Severity of Illness Index; Survival Analysis | 2017 |
How Antibiotics Should be Prescribed to Hospitalized Elderly Patients with Community-Acquired Pneumonia.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Fluoroquinolones; Hospitalization; Humans; Influenza Vaccines; Macrolides; Methicillin-Resistant Staphylococcus aureus; Pneumococcal Vaccines; Pneumonia, Bacterial; Practice Guidelines as Topic; Pseudomonas aeruginosa; Time-to-Treatment | 2017 |
Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis.
Topics: Adult; Bacteremia; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Fluoroquinolones; Hospitalization; Humans; Macrolides; Odds Ratio; Pneumonia, Bacterial; Shock, Septic; Treatment Outcome | 2017 |
Clinical significance of extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Male; Middle Aged; Risk Factors | 2008 |
Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; beta-Lactams; Chi-Square Distribution; Community-Acquired Infections; Drug Therapy, Combination; Fluoroquinolones; Humans; Length of Stay; Macrolides; Odds Ratio; Pneumonia; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Addressing the challenge of extended-spectrum beta-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome; Urinary Tract Infections | 2009 |
New antimicrobial molecules and new antibiotic strategies.
Topics: Acetamides; Anti-Infective Agents; beta-Lactams; Cephalosporins; Community-Acquired Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Ertapenem; Fluoroquinolones; Humans; Ketolides; Linezolid; Lipopeptides; Oxazolidinones; Pneumonia, Bacterial; Practice Guidelines as Topic | 2009 |
Streptococcus pneumoniae: does antimicrobial resistance matter?
Topics: Anti-Bacterial Agents; beta-Lactams; California; Canada; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Evidence-Based Medicine; Humans; Penicillin Resistance; Penicillins; Pneumococcal Vaccines; Pneumonia, Pneumococcal; Prevalence; Risk Assessment; Risk Factors; Streptococcal Infections; Streptococcus pneumoniae | 2009 |
Community-acquired methicillin-resistant Staphylococcus aureus: what do we need to know?
Topics: Bacterial Toxins; Bacterial Typing Techniques; beta-Lactams; Community-Acquired Infections; Cross Infection; DNA Fingerprinting; Europe; Exotoxins; Genotype; Humans; Leukocidins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; North America; Risk Factors; Staphylococcal Infections; Virulence Factors | 2009 |
Ertapenem.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Ertapenem; Half-Life; Humans; Outpatients | 2010 |
Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia.
Topics: Administration, Oral; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Costs; Drug Therapy, Combination; Fluoroquinolones; Humans; Infusions, Intravenous; Length of Stay; Macrolides; Pneumonia; Severity of Illness Index; Treatment Outcome; United States | 2010 |
Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome; Young Adult | 2010 |
Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?
Topics: Anti-Bacterial Agents; beta-Lactams; Clinical Trials as Topic; Community-Acquired Infections; Drug Therapy, Combination; Fluoroquinolones; Hospitals, General; Humans; Macrolides; Pneumonia, Bacterial | 2013 |
[New approaches to antibacterial therapy of infections in the surgical practice].
Topics: Abdominal Abscess; Aza Compounds; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Cross Infection; Ertapenem; Fluoroquinolones; Humans; Lactams; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Surgical Wound Infection | 2003 |
Resistance to beta-lactams--the permutations.
Topics: beta-Lactam Resistance; beta-Lactams; Biological Availability; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Sensitivity and Specificity | 2003 |
Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Carbapenems; Community-Acquired Infections; Ertapenem; Humans; Lactams | 2004 |
In vitro activity of ertapenem: review of recent studies.
Topics: Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Lactams; Microbial Sensitivity Tests | 2004 |
Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Clinical Trials as Topic; Community-Acquired Infections; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Renal Insufficiency | 2004 |
Safety and tolerability of ertapenem.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Ceftriaxone; Clinical Trials as Topic; Community-Acquired Infections; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic | 2004 |
Appropriate use of the carbapenems.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Carbapenems; Cilastatin; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Ertapenem; Humans; Imipenem; Lactams; Meropenem; Patient Selection; Pneumonia, Bacterial; Practice Patterns, Physicians'; Protease Inhibitors; South Africa; Surgical Wound Infection; Thienamycins; Urinary Tract Infections | 2004 |
Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Double-Blind Method; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Role of beta-lactam agents in the treatment of community-acquired pneumonia.
Topics: Adult; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Child, Preschool; Community-Acquired Infections; Haemophilus influenzae; Humans; Infant; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Treatment Outcome | 2005 |
Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program.
Topics: Azithromycin; beta-Lactams; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Macrolides; Microbial Sensitivity Tests | 2005 |
Current guidelines for the treatment of severe pneumonia and sepsis.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Critical Illness; Cross Infection; Drug Resistance; Germany; Humans; Intensive Care Units; International Cooperation; Pneumonia; Practice Guidelines as Topic; Sepsis; Severity of Illness Index | 2005 |
Comparison of amoxicillin with alternative agents for the treatment of acute otitis media in children.
Topics: Acute Disease; Amoxicillin; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Child; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Otitis Media | 2005 |
MRSA--the tip of the iceberg.
Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Community-Acquired Infections; Gram-Positive Bacteria; Humans; Methicillin Resistance; Staphylococcal Infections; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2006 |
Monotherapy versus Combination Therapy in Patients Hospitalized with Community-Acquired Pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Humans; Legionella pneumophila; Pneumonia, Bacterial; Prospective Studies | 2006 |
Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Clinical Trials as Topic; Community-Acquired Infections; Critical Illness; Drug Interactions; Drug Resistance, Bacterial; Endometritis; Ertapenem; Female; Humans; Peritonitis; Protein Binding; Renal Insufficiency; Surgical Wound Infection; Urinary Tract Infections | 2007 |
[Betalactam antibiotics combined with bectalactamases inhibitors. Amoxicillin-sulbactam].
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Sulbactam | 2008 |
Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia.
Topics: Administration, Oral; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactams; Clinical Trials as Topic; Community-Acquired Infections; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Injections, Intravenous; Patient Satisfaction; Pneumonia; Treatment Outcome | 1998 |
[Oral beta-lactam antibiotics in the treatment of respiratory tract infections].
Topics: Administration, Oral; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Community-Acquired Infections; Humans; Penicillins; Respiratory Tract Infections | 2001 |
Beta-lactam/beta-lactamase inhibitor combinations in empiric management of pediatric infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactams; Child; Community-Acquired Infections; Drug Tolerance; Enzyme Inhibitors; Humans; Patient Compliance; Safety | 2002 |
Beta-lactam resistance: clinical implications for pediatric patients.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactam Resistance; beta-Lactams; Child; Community-Acquired Infections; Cross Infection; Humans; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus | 2002 |
Community-acquired lower respiratory tract infections: clinical experience with beta-lactam/beta-lactamase inhibitors.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Humans; Respiratory Tract Infections | 2002 |
27 trial(s) available for beta-lactams and Community Acquired Infection
| Article | Year |
|---|---|
Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactams; Child, Preschool; Community-Acquired Infections; Diarrhea; Gastrointestinal Microbiome; Humans; Infant; Pneumonia | 2022 |
Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Community-Acquired Infections; Humans; Infant; Microbiota; Pneumonia | 2022 |
Accuracy of a score predicting the presence of an atypical pathogen in hospitalized patients with moderately severe community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; beta-Lactams; Community-Acquired Infections; Humans; Pneumonia | 2022 |
Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Community-Acquired Infections; Double-Blind Method; Drug Administration Schedule; Drug Costs; Drug Resistance, Bacterial; Equivalence Trials as Topic; Female; Hospitalization; Humans; Infant; Infant, Newborn; Intention to Treat Analysis; Male; Middle Aged; Pneumonia; Treatment Outcome; Young Adult | 2021 |
Response Adjusted for Days of Antibiotic Risk (RADAR): evaluation of a novel method to compare strategies to optimize antibiotic use.
Topics: Adult; Anti-Bacterial Agents; Antimicrobial Stewardship; beta-Lactams; Community-Acquired Infections; Fluoroquinolones; Humans; Pneumonia, Bacterial; Treatment Outcome | 2017 |
Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Length of Stay; Macrolides; Male; Middle Aged; Netherlands; Outcome Assessment, Health Care; Pneumonia; Tetracycline; Treatment Outcome | 2017 |
Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Community-Acquired Infections; Female; Fluoroquinolones; Heart Diseases; Hospitalization; Humans; Macrolides; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies | 2019 |
Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Female; Humans; Inflammation; Lipopolysaccharides; Male; Middle Aged; Netherlands; Plasma; Pneumonia, Pneumococcal; Rifampin; Teichoic Acids; Treatment Outcome; Young Adult | 2019 |
Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Double-Blind Method; Ertapenem; Female; Humans; Intraabdominal Infections; Male; Middle Aged; Young Adult | 2014 |
Antibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicentre cluster-randomised cross-over trial.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Cross-Over Studies; Drug Therapy, Combination; Fluoroquinolones; Humans; Macrolides; Observational Studies as Topic; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Research Design; Severity of Illness Index | 2014 |
β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Follow-Up Studies; Hospitalization; Humans; Legionella pneumophila; Legionnaires' Disease; Macrolides; Middle Aged; Odds Ratio; Pneumonia, Bacterial; Severity of Illness Index; Switzerland; Treatment Outcome | 2014 |
Antibiotic treatment strategies for community-acquired pneumonia in adults.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Cross-Over Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Intention to Treat Analysis; Length of Stay; Macrolides; Male; Middle Aged; Pneumonia, Bacterial | 2015 |
Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Cost-Benefit Analysis; Cross-Over Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Macrolides; Male; Middle Aged; Netherlands; Pneumonia, Bacterial | 2017 |
[Septic shock due to community-acquired complicated intra-abdominal infection treated with ertapenem: outcome in 25 cases].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Community-Acquired Infections; Critical Care; Emergencies; Ertapenem; Female; Hospital Mortality; Humans; Intestinal Perforation; Length of Stay; Male; Middle Aged; Peritonitis; Prospective Studies; Shock, Septic; Survival Analysis; Treatment Outcome | 2008 |
Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Child; Child, Preschool; Community-Acquired Infections; Double-Blind Method; Ertapenem; Female; Humans; Infant; Male; Molecular Sequence Data; Pneumonia, Bacterial; Skin Diseases, Bacterial; Soft Tissue Infections; Urinary Tract Infections | 2009 |
Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome; Young Adult | 2010 |
A prospective, multi centre, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin-Sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection. (T.E.A. Study: Three days Ertapene
Topics: Abdomen; Adult; Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Clinical Protocols; Community-Acquired Infections; Drug Therapy, Combination; Ertapenem; Humans; Peritonitis; Sulbactam | 2011 |
Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Health Care Costs; Humans; Length of Stay; Macrolides; Male; Middle Aged; Moxifloxacin; Pneumonia; Quinolines; Treatment Failure | 2012 |
A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Ertapenem; Europe; Female; Hospitalization; Humans; Injections, Intramuscular; Injections, Intravenous; Lactams; Latin America; Male; Middle Aged; Pneumonia, Pneumococcal; Prospective Studies; Severity of Illness Index; Streptococcus pneumoniae; Treatment Outcome; United States | 2002 |
Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Chi-Square Distribution; Clostridioides difficile; Community-Acquired Infections; Diarrhea; Female; Humans; Levofloxacin; Male; Ofloxacin; Prospective Studies; Respiratory Tract Infections | 2003 |
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2003 |
Ertapenem therapy for community-acquired pneumonia in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Logistic Models; Male; Odds Ratio; Pneumonia, Pneumococcal; Retrospective Studies; Statistics, Nonparametric; Streptococcus pneumoniae; Treatment Outcome | 2003 |
Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Child; Child, Preschool; Community-Acquired Infections; Double-Blind Method; Ertapenem; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Lactams; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2004 |
Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; beta-Lactams; Bronchoalveolar Lavage Fluid; Community-Acquired Infections; Drug Administration Schedule; Ertapenem; Female; Half-Life; Humans; Injections, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Pulmonary Alveoli; Respiratory Mucosa; Thoracotomy | 2005 |
The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Decision Support Techniques; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Length of Stay; Macrolides; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pneumonia, Bacterial; Probability; Prospective Studies; Severity of Illness Index; Shock, Septic; Survival Analysis; Survival Rate | 2007 |
A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs >or=5 days in community-acquired intraabdominal infection.
Topics: Anti-Bacterial Agents; APACHE; Appendicitis; beta-Lactams; Community-Acquired Infections; Double-Blind Method; Ertapenem; Humans; Peritonitis; Prospective Studies; Surgical Wound Infection | 2008 |
A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Tolerance; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2002 |
147 other study(ies) available for beta-lactams and Community Acquired Infection
| Article | Year |
|---|---|
Effectiveness of Beta-Lactam plus Doxycycline for Patients Hospitalized with Community-Acquired Pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Humans; Pneumonia; Retrospective Studies | 2022 |
Cost of antibiotics in medical intensive care.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Critical Care; Cross Infection; Drug Utilization; Humans; Retrospective Studies | 2022 |
Pneumococcal urinary antigen testing for antimicrobial guidance in community-acquired pneumonia-A register-based cohort study.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; beta-Lactams; Cohort Studies; Community-Acquired Infections; Humans; Pneumonia, Pneumococcal; Retrospective Studies; Streptococcus pneumoniae | 2022 |
Antimicrobial therapy of community-acquired pneumonia during stewardship efforts and a coronavirus pandemic: an observational study.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Community-Acquired Infections; Coronavirus; Humans; Pandemics; Pneumonia; Retrospective Studies | 2022 |
Beta-Lactam Plus Macrolide for Patients Hospitalized With Community-Acquired Pneumonia: Difference Between Autumn and Spring.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Macrolides; Male; Pneumonia, Bacterial; Retrospective Studies; Seasons | 2022 |
[Clarithromycin for community-acquired pneumonia in adults: focus on anti-inflammatory properties].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; C-Reactive Protein; Clarithromycin; Community-Acquired Infections; Female; Humans; Interleukin-6; Male; Middle Aged; Pneumonia; Tumor Necrosis Factor-alpha; Young Adult | 2023 |
Early discontinuation of combination antibiotic therapy in severe community-acquired pneumonia: a retrospective cohort study.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; beta-Lactams; Community-Acquired Infections; Humans; Influenza, Human; Lactams; Legionnaires' Disease; Pneumonia, Mycoplasma; Quinolones; Retrospective Studies | 2023 |
β-Lactams plus doxycycline versus azithromycin for treatment of severe community-acquired pneumonia in critically ill patients.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Community-Acquired Infections; Critical Illness; Doxycycline; Drug Therapy, Combination; Humans; Pneumonia; Prospective Studies; Treatment Outcome | 2023 |
Empiric Anti-Pseudomonal β-Lactam Monotherapy Versus Fluoroquinolone Combination Therapy in Patients With Hospital-Acquired Pneumonia: A Multicenter Cohort Study With Propensity Score Matching.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Fluoroquinolones; Hospitals; Humans; Pneumonia; Propensity Score; Retrospective Studies | 2023 |
Fluoroquinolone Monotherapy and Combination of a Fluoroquinolone With a β-Lactam: Different Therapies for Different Types of Patients With Community-Acquired Pneumonia.
Topics: beta-Lactams; Community-Acquired Infections; Fluoroquinolones; Humans; Macrolides; Pneumonia | 2019 |
Response.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Humans; Macrolides; Pneumonia | 2019 |
Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Europe; Female; Hospitalization; Humans; Machine Learning; Macrolides; Male; Middle Aged; Pneumonia, Bacterial; Propensity Score; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2019 |
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.
Topics: Adult; Ambulatory Care; Anti-Bacterial Agents; Antigens, Bacterial; beta-Lactams; Blood Culture; Chlamydophila Infections; Community-Acquired Infections; Culture Techniques; Drug Therapy, Combination; Haemophilus Infections; Hospitalization; Humans; Legionellosis; Macrolides; Moraxellaceae Infections; Pneumonia, Bacterial; Pneumonia, Mycoplasma; Pneumonia, Pneumococcal; Pneumonia, Staphylococcal; Radiography, Thoracic; Severity of Illness Index; Sputum; United States | 2019 |
Impact of Beta-lactam Allergy on Treatment of Outpatient Infections.
Topics: Ambulatory Care; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Drug Hypersensitivity; Humans; Inappropriate Prescribing; Retrospective Studies | 2019 |
Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Clarithromycin; Cohort Studies; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Macrolides; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2020 |
Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Bacteremia; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Male; Pneumonia, Bacterial; Prospective Studies; Severity of Illness Index; Survival Analysis | 2019 |
Diagnosis and Treatment of Adults With Community-Acquired Pneumonia.
Topics: Adult; beta-Lactams; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Macrolides; Pneumonia; Streptococcus pneumoniae | 2020 |
The increased frequency of methicillin-resistant Staphylococcus aureus with low MIC of beta-lactam antibiotics isolated from hospitalized patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Female; Genotype; Humans; Japan; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Protein Structure, Tertiary; Staphylococcal Infections; Whole Genome Sequencing | 2020 |
Antibiotic treatment with one single dose of gentamicin at admittance in addition to a β-lactam antibiotic in the treatment of community-acquired bloodstream infection with sepsis.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Bacteremia; Bacteria; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Gentamicins; Hospitalization; Humans; Male; Organ Dysfunction Scores; Retrospective Studies; Sepsis | 2020 |
Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
Topics: Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Community-Acquired Infections; Drug Therapy, Combination; Humans; Intensive Care Units; Macrolides; Pneumonia, Bacterial; Propensity Score; Prospective Studies; Treatment Outcome | 2021 |
Risk factors for complicated community-acquired pneumonia course in patients treated with β-lactam monotherapy.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Female; Humans; Male; Pneumonia, Bacterial; Prospective Studies; Severity of Illness Index; Treatment Outcome | 2021 |
In moderately severe CAP stable after 3 d of β-lactam, stopping therapy was noninferior to 5 additional d.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Double-Blind Method; Humans; Pneumonia, Bacterial; Treatment Outcome | 2021 |
Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.
Topics: Adult; Alanine Transaminase; Anti-Bacterial Agents; Aspartate Aminotransferases; beta-Lactams; Bilirubin; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Respiratory Distress Syndrome; Retrospective Studies | 2017 |
The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cause of Death; Cohort Studies; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Length of Stay; Logistic Models; Macrolides; Male; Middle Aged; Pneumonia, Bacterial; Time Factors; Treatment Outcome | 2018 |
Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Enterobacteriaceae; Enterobacteriaceae Infections; Feces; Female; Humans; Male; Retrospective Studies; Urinary Tract Infections | 2017 |
Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Critical Illness; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Lactic Acid; Length of Stay; Logistic Models; Macrolides; Male; Middle Aged; Organ Dysfunction Scores; Pneumonia, Bacterial; Prognosis; Prospective Studies; Severity of Illness Index; Time Factors | 2018 |
Macrolides and Pediatric Community-Acquired Pneumonia-Time for a Paradigm Shift?
Topics: beta-Lactams; Child; Community-Acquired Infections; Humans; Macrolides; Pneumonia | 2017 |
Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Community-Acquired Infections; Drug Therapy, Combination; Hospitalization; Humans; Infant; Intensive Care Units, Pediatric; Length of Stay; Macrolides; Patient Readmission; Pneumonia, Bacterial; Propensity Score; Radiography; Treatment Outcome | 2017 |
Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients.
Topics: Abdomen; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; China; Community-Acquired Infections; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Incidence; Intraabdominal Infections; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests | 2017 |
Empiric antibiotics for community-acquired pneumonia: A macrolide and a beta-lactam please!
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Humans; Macrolides; Pneumonia; Pneumonia, Bacterial | 2018 |
Reconsidering Treatment of Community-Acquired Pneumonia: Are Macrolides Plus β-Lactams Essential?
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Humans; Macrolides; Pneumonia; Streptococcus pneumoniae | 2018 |
Effects of age, comorbidity and adherence to current antimicrobial guidelines on mortality in hospitalized elderly patients with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; beta-Lactams; China; Community-Acquired Infections; Comorbidity; Female; Fluoroquinolones; Guideline Adherence; Hospital Mortality; Humans; Male; Pneumonia; Retrospective Studies; Risk Factors | 2018 |
Benzylpenicillin versus wide-spectrum beta-lactam antibiotics as empirical treatment of Haemophilus influenzae-associated lower respiratory tract infections in adults; a retrospective propensity score-matched study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Child; Child, Preschool; Community-Acquired Infections; Female; Haemophilus Infections; Haemophilus influenzae; Hospitalization; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Middle Aged; Penicillin G; Pneumonia; Propensity Score; Respiratory Tract Infections; Retrospective Studies; Sweden; Young Adult | 2018 |
Antibiotic treatment outcomes in community-acquired pneumonia
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Hospital Departments; Hospital Mortality; Hospitals; Humans; Length of Stay; Macrolides; Male; Middle Aged; Pneumonia; Prospective Studies; Pseudomonas aeruginosa; Streptococcus pneumoniae; Treatment Outcome; Turkey | 2018 |
Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cause of Death; Community-Acquired Infections; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Length of Stay; Macrolides; Male; Middle Aged; Pneumonia, Pneumococcal; Propensity Score; Prospective Studies; Spain; Sputum; Streptococcus pneumoniae; Survival Rate | 2019 |
Prescribing trends and revisit rates following a pharmacist-driven protocol change for community-acquired pneumonia in an emergency department.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Prescriptions; Drug Therapy, Combination; Emergency Service, Hospital; Female; Humans; Macrolides; Male; Middle Aged; Patient Readmission; Pharmacists; Pneumonia; Practice Patterns, Physicians'; Retrospective Studies | 2019 |
Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Hospital Mortality; Hospitalization; Humans; Japan; Levofloxacin; Male; Middle Aged; Pneumonia, Bacterial; Severity of Illness Index; Treatment Outcome | 2019 |
A 10 year surveillance for antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae in community- and hospital-associated intra-abdominal infections in China.
Topics: Anti-Bacterial Agents; beta-Lactams; China; Community-Acquired Infections; Cross Infection; Ertapenem; Escherichia coli; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Prevalence | 2013 |
Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: therapeutic guidelines might not always fit with and everyday experience.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Child; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Gentamicins; Hospitals, Pediatric; Humans; Italy; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Sulbactam; Thienamycins | 2013 |
Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; beta-Lactams; Chlamydial Pneumonia; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Guideline Adherence; Hospitalization; Humans; Immunocompromised Host; Legionnaires' Disease; Macrolides; Male; Middle Aged; Odds Ratio; Pneumonia, Bacterial; Pneumonia, Mycoplasma; Pneumonia, Pneumococcal; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Severity of Illness Index | 2013 |
Characteristics of community-onset NDM-1-producing Klebsiella pneumoniae isolates.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Conjugation, Genetic; Gene Order; Genotype; Humans; Klebsiella Infections; Klebsiella pneumoniae; Korea; Male; Molecular Typing; Plasmids | 2014 |
Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Critical Illness; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; France; Humans; Intensive Care Units; Macrolides; Male; Middle Aged; Multivariate Analysis; Pneumonia, Bacterial; Prospective Studies; Risk Assessment; Survival Analysis; Time Factors | 2013 |
Prevalence of extended-spectrum β-lactamase-producing multidrug-resistant Escherichia coli among isolates from community-acquired infections and in silico structural modeling of an ESBL protein.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Computer Simulation; Escherichia coli; Escherichia coli Infections; Humans; India; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Prevalence; Sequence Alignment | 2014 |
Fecal carriage rates of extended-spectrum β-lactamase-producing Escherichia coli among antibiotic naive healthy human volunteers.
Topics: Adult; Anti-Bacterial Agents; Asymptomatic Diseases; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carrier State; Clone Cells; Community-Acquired Infections; Cross Infection; Disease Reservoirs; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Feces; Humans; India; Prevalence; Rural Population | 2015 |
Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections in a pediatric hospital in Argentina.
Topics: Adolescent; Anti-Bacterial Agents; Argentina; beta-Lactams; Child; Child, Preschool; Community-Acquired Infections; Electrophoresis, Gel, Pulsed-Field; Female; Genotype; Hospitals, Pediatric; Humans; Infant; Longitudinal Studies; Male; Methicillin-Resistant Staphylococcus aureus; Molecular Typing; Soft Tissue Infections; Staphylococcal Skin Infections; Virulence Factors | 2014 |
Comparison of the effectiveness and antibiotic cost among ceftriaxone, ertapenem, and levofloxacin in treatment of community-acquired complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Costs and Cost Analysis; Ertapenem; Escherichia coli; Female; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Urinary Tract Infections; Young Adult | 2016 |
Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
Topics: Anti-Bacterial Agents; APACHE; beta-Lactams; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Ertapenem; Humans; Intraabdominal Infections; Length of Stay; Models, Economic; Monte Carlo Method; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Spain | 2015 |
β-lactam monotherapy is non-inferior to combination treatment for community-acquired pneumonia.
Topics: beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Fluoroquinolones; Humans; Macrolides; Pneumonia; Randomized Controlled Trials as Topic | 2015 |
Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.
Topics: Adolescent; Age Factors; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Infant; Macrolides; Male; Outpatients; Pneumonia, Bacterial; Retrospective Studies; Treatment Failure; Treatment Outcome | 2016 |
Comparative Treatment Failure Rates of Respiratory Fluoroquinolones or β-Lactam + Macrolide Versus β-Lactam Alone in the Treatment for Community-Acquired Pneumonia in Adult Outpatients: An Analysis of a Nationally Representative Claims Database.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Databases, Factual; Female; Fluoroquinolones; Humans; Insurance Claim Review; Macrolides; Male; Middle Aged; Pneumonia, Bacterial; Taiwan; Treatment Failure | 2015 |
Antibiotic Resistance, Virulence, and Genetic Background of Community-Acquired Uropathogenic Escherichia coli from Algeria.
Topics: Adult; Aged; Algeria; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Community-Acquired Infections; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Escherichia coli Infections; Female; Fluoroquinolones; Gene Expression; Genotype; Humans; Integrons; Male; Microbial Sensitivity Tests; Middle Aged; Multilocus Sequence Typing; Mutation; Phylogeny; Polymerase Chain Reaction; Sulfonamides; Trimethoprim; Uropathogenic Escherichia coli; Virulence | 2015 |
Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoxitin; China; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Gene Expression; Humans; Imipenem; Intraabdominal Infections; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2016 |
[Comparison of the combination and quinolone therapy in community acquired pneumonia].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Length of Stay; Macrolides; Male; Pneumonia, Bacterial; Treatment Outcome | 2015 |
The use of ertapenem for the treatment of community-acquired pneumonia in routine hospital practice: a matched cohort study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Community-Acquired Infections; Comorbidity; Ertapenem; Female; Frail Elderly; Hospitalization; Humans; Male; Middle Aged; Nursing Homes; Pneumonia; Retrospective Studies; Risk Factors | 2016 |
Tetracyclic indolines as a novel class of β-lactam-selective resistance-modifying agent for MRSA.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Synergism; Humans; Indoles; Methicillin-Resistant Staphylococcus aureus; Structure-Activity Relationship; Tetracyclines | 2017 |
Community-Acquired Pneumonia in Adults: Diagnosis and Management.
Topics: Acetamides; Adult; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Macrolides; Male; Oxazolidinones; Pneumonia, Bacterial; Vancomycin | 2016 |
Narrow-spectrum ß-lactam monotherapy in hospital treatment of community-acquired pneumonia: a register-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Community-Acquired Infections; Comorbidity; Female; Hospitalization; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Odds Ratio; Pneumonia, Bacterial; Treatment Outcome | 2017 |
Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospital-acquired versus community-acquired urinary tract infections and ICU- versus non-ICU-associated intra-abdominal infections.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefoxitin; Community-Acquired Infections; Cross Infection; Enterobacteriaceae; Ertapenem; Escherichia coli; Humans; Imipenem; Intensive Care Units; Intraabdominal Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Turkey; Urinary Tract Infections | 2017 |
[In vitro activity of ertapenem against clinical bacterial isolates in 69 Spanish medical centers (E-test study)].
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Ertapenem; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Spain | 2007 |
Implication of clinical pathway care for community-acquired pneumonia in a community hospital: early switch from an intravenous beta-lactam plus a macrolide to an oral respiratory fluoroquinolone.
Topics: Administration, Inhalation; Administration, Oral; Aged; Aged, 80 and over; beta-Lactams; Cohort Studies; Community-Acquired Infections; Critical Pathways; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitals, Community; Humans; Infusions, Intravenous; Macrolides; Male; Middle Aged; Pneumonia; Retrospective Studies | 2008 |
Treatment of community-acquired pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Macrolides; Pneumonia | 2008 |
Predominance of CTX-M-15 extended spectrum beta-lactamases in diverse Escherichia coli and Klebsiella pneumoniae from hospital and community patients in Kuwait.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Cross Infection; Escherichia coli; Escherichia coli Infections; Hospitals; Humans; Klebsiella Infections; Klebsiella pneumoniae; Kuwait | 2009 |
The science of selecting antimicrobials for community-acquired pneumonia (CAP).
Topics: Anti-Bacterial Agents; beta-Lactams; Chlamydophila pneumoniae; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Legionnaires' Disease; Macrolides; Microbial Sensitivity Tests; Pneumonia, Bacterial; Practice Guidelines as Topic; Streptococcus pneumoniae | 2009 |
Prevalence of Panton-Valentine leukocidin genes in methicillin-resistant Staphylococcus aureus isolates phenotypically consistent with community-acquired MRSA, 1999-2007, Vienna General Hospital.
Topics: Anti-Bacterial Agents; Austria; Bacterial Proteins; Bacterial Toxins; beta-Lactams; Community-Acquired Infections; Exotoxins; Hospitals, General; Humans; Leukocidins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Prevalence; Staphylococcal Infections; Virulence Factors | 2009 |
Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Inpatients; Macrolides; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome | 2009 |
Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Ciprofloxacin; Community-Acquired Infections; DNA Gyrase; DNA Mutational Analysis; DNA Transposable Elements; Fluoroquinolones; Gene Expression Profiling; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Nafcillin; Ofloxacin; Penicillin-Binding Proteins; Selection, Genetic; SOS Response, Genetics; Staphylococcal Infections; Transcription Factors; Up-Regulation | 2009 |
Risk factors for recurrence after Staphylococcus aureus bacteraemia. A retrospective matched case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactams; Case-Control Studies; Catheter-Related Infections; Catheterization, Central Venous; Child; Child, Preschool; Community-Acquired Infections; Cross Infection; Female; Glycopeptides; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Practice Guidelines as Topic; Recurrence; Retrospective Studies; Risk Factors; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Young Adult | 2009 |
Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Case-Control Studies; Community-Acquired Infections; Ertapenem; Female; Hospitals; Humans; Length of Stay; Male; Pneumonia; Retrospective Studies; Severity of Illness Index; Spain; Treatment Outcome | 2009 |
Comparison of initial antibiotic choice and treatment of cellulitis in the pre- and post-community-acquired methicillin-resistant Staphylococcus aureus eras.
Topics: Anti-Bacterial Agents; beta-Lactams; Cellulitis; Community-Acquired Infections; Humans; Methicillin Resistance; Military Personnel; Practice Patterns, Physicians'; Retrospective Studies; Staphylococcal Infections; Treatment Failure; United States | 2009 |
Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactams; Bronchiolitis; Community-Acquired Infections; Critical Care; Cystic Fibrosis; Humans; Inflammation; Macrolides; Pneumonia; Randomized Controlled Trials as Topic; Sepsis; Treatment Outcome | 2009 |
Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; beta-Lactams; Cohort Studies; Community-Acquired Infections; Drug Therapy, Combination; Female; Guideline Adherence; Humans; Length of Stay; Male; Pneumonia; Retrospective Studies | 2009 |
Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Child; Child, Preschool; Community-Acquired Infections; Cross Infection; Escherichia coli; Escherichia coli Infections; Female; Hospitals; Humans; Infant; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Saudi Arabia; Young Adult | 2009 |
[Treatment of community-acquired pneumonia in adults: ertapenem versus cefditoren?].
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Ertapenem; Humans; Ofloxacin; Pneumonia, Bacterial | 2010 |
Clinical, molecular and epidemiological description of a cluster of community-associated methicillin-resistant Staphylococcus aureus isolates from injecting drug users with bacteraemia.
Topics: Adult; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactams; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Drug Users; Erythromycin; Fusidic Acid; Gentamicins; Humans; Male; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Epidemiology; Phenotype; Staphylococcal Infections; United Kingdom; Young Adult | 2010 |
Activity of ertapenem, ciprofloxacin, ceftriaxone, piperacillin-tazobactam, and ampicillin-sulbactam against 12 common clinical isolates of community-acquired bacteremia.
Topics: Anti-Bacterial Agents; Bacteremia; Bacteria; Bacterial Typing Techniques; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Drug Resistance, Bacterial; Escherichia coli Infections; Humans; Klebsiella Infections; Microbial Sensitivity Tests; Taiwan | 2009 |
Changing prevalence of Escherichia coli with CTX-M-type extended-spectrum beta-lactamases in outpatient urinary E. coli between 2003 and 2008.
Topics: Ambulatory Care; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Ertapenem; Escherichia coli Infections; Escherichia coli Proteins; Genotype; Humans; Nitrofurantoin; Prevalence; Urinary Tract Infections; Urine; Uropathogenic Escherichia coli | 2010 |
Antibiotic dose impact on resistance selection in the community: a mathematical model of beta-lactams and Streptococcus pneumoniae dynamics.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Humans; Models, Biological; Pneumococcal Infections; Streptococcus pneumoniae | 2010 |
Population analysis and epidemiological features of inhibitor-resistant-TEM-beta-lactamase-producing Escherichia coli isolates from both community and hospital settings in Madrid, Spain.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Cross Infection; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Phylogeny; Plasmids; Sequence Analysis, DNA; Spain | 2010 |
CTX-M type extended spectrum beta-lactamases in Escherichia coli isolates from community acquired upper urinary tract infections at a university in the European part of Turkey.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Community-Acquired Infections; DNA, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Genotype; Hospitals, University; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Polymerase Chain Reaction; Sequence Analysis, DNA; Turkey; Urinary Tract Infections | 2010 |
CTX-M-producing Escherichia coli in a maternity ward: a likely community importation and evidence of mother-to-neonate transmission.
Topics: Adult; Anti-Bacterial Agents; Bacterial Typing Techniques; beta-Lactamases; beta-Lactams; Community-Acquired Infections; DNA Fingerprinting; Electrophoresis, Gel, Pulsed-Field; Environmental Microbiology; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; France; Genotype; Hospitals, Maternity; Hospitals, University; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Microbial Sensitivity Tests; Plasmids; Pregnancy | 2010 |
Viral and Mycoplasma pneumoniae community-acquired pneumonia and novel clinical outcome evaluation in ambulatory adult patients in China.
Topics: Adult; Age Factors; Anti-Bacterial Agents; beta-Lactams; China; Community-Acquired Infections; Female; Humans; Legionella pneumophila; Macrolides; Male; Middle Aged; Mycoplasma pneumoniae; Pneumonia, Bacterial; Pneumonia, Mycoplasma; Pneumonia, Viral; Quinolones; Sputum; Streptococcus pneumoniae; Treatment Outcome | 2010 |
Does radiographic evidence of prior pulmonary tubercular infection influence the choice of empiric antibiotics for community-acquired pneumonia in a tuberculosis-endemic area?
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Clinical Protocols; Community-Acquired Infections; Comorbidity; Endemic Diseases; Fluoroquinolones; Humans; Middle Aged; Pneumonia; Radiography; Retrospective Studies; Treatment Outcome; Tuberculosis | 2010 |
[Evolution of Escherichia coli resistance in community acquired peritonitis].
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Appendicitis; beta-Lactams; Cephalosporins; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Intestines; Male; Morocco; Peptic Ulcer Perforation; Peritonitis; Practice Guidelines as Topic; Prospective Studies | 2011 |
Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Child; Child, Preschool; Community-Acquired Infections; Disk Diffusion Antimicrobial Tests; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Female; Follow-Up Studies; Hospitals; Humans; Infant; Male; Pyelonephritis; Recurrence; Retrospective Studies; Turkey; Urinary Tract Infections | 2011 |
Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
[Methicillin-resistant Staphylococcus aureus in children attending school in Cartagena, Colombia].
Topics: Anti-Bacterial Agents; beta-Lactams; Carrier State; Child; Child, Preschool; Colombia; Community-Acquired Infections; Cross Infection; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Female; Humans; Infant; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Nasal Cavity; Risk; Staphylococcal Infections; Superinfection | 2010 |
Variability in pediatric infectious disease consultants' recommendations for management of community-acquired pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactams; Clindamycin; Community-Acquired Infections; Data Collection; Humans; Methicillin-Resistant Staphylococcus aureus; Pneumonia; Vancomycin | 2011 |
Diagnosis and management of community-acquired pneumonia in adults.
Topics: Acetamides; Adult; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactams; Community-Acquired Infections; Diagnosis, Differential; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Humans; Influenza Vaccines; Linezolid; Macrolides; Oxazolidinones; Pneumococcal Vaccines; Pneumonia, Bacterial; Practice Guidelines as Topic; Risk Factors; Treatment Outcome; United States; Vancomycin | 2011 |
In vitro activity of beta-lactam antibiotics to community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2012 |
Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Belgium; beta-Lactams; Child; Child, Preschool; Clarithromycin; Community-Acquired Infections; Comorbidity; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia, Pneumococcal; Quinolines; Streptococcus pneumoniae; Vaccination; Young Adult | 2012 |
Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Australia; beta-Lactams; Chlamydophila; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Female; Gram-Negative Bacterial Infections; Humans; Legionella; Macrolides; Male; Middle Aged; Mycoplasma; Mycoplasma Infections; Pneumonia, Bacterial; Prospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2012 |
Procalcitonin predicts response to beta-lactam treatment in hospitalized children with community-acquired pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Calcitonin; Calcitonin Gene-Related Peptide; Child; Child, Hospitalized; Child, Preschool; Cohort Studies; Coinfection; Community-Acquired Infections; Humans; Infant; Male; Odds Ratio; Paris; Pneumonia, Bacterial; Predictive Value of Tests; Protein Precursors; Retrospective Studies; Sensitivity and Specificity | 2012 |
Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments.
Topics: Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Cohort Studies; Community-Acquired Infections; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Hospitalization; Humans; Internal Medicine; Israel; Male; Odds Ratio; Prevalence; Retrospective Studies; Risk Factors; Urinary Tract Infections | 2012 |
Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002-2010.
Topics: Anti-Bacterial Agents; Asia; Australasia; beta-Lactams; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Global Health; Humans; Microbial Sensitivity Tests | 2012 |
Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Binomial Distribution; Child; Child, Preschool; Cohort Studies; Community-Acquired Infections; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Humans; Infant; Length of Stay; Logistic Models; Macrolides; Male; Patient Readmission; Pneumonia, Bacterial; Retrospective Studies; Treatment Outcome | 2012 |
Comparative genomics of community-acquired ST59 methicillin-resistant Staphylococcus aureus in Taiwan: novel mobile resistance structures with IS1216V.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; beta-Lactams; Chromosomes, Bacterial; Community-Acquired Infections; DNA Restriction-Modification Enzymes; Drug Resistance, Multiple, Bacterial; Enterococcus faecalis; Exotoxins; Genome, Bacterial; Genomics; Humans; Interspersed Repetitive Sequences; Leukocidins; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Sequence Data; Staphylococcal Infections; Taiwan; Tetracycline | 2012 |
The emergence and dissemination of CTX-M-producing Escherichia coli sequence type 131 causing community-onset bacteremia in Israel.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamases; beta-Lactams; Community-Acquired Infections; DNA, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Incidence; Israel; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Multilocus Sequence Typing; Polymerase Chain Reaction; Prevalence; Retrospective Studies | 2013 |
Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Cross Infection; Drug Therapy, Combination; Female; Hospital Mortality; Humans; Intensive Care Units; Male; Middle Aged; Practice Patterns, Physicians'; Sepsis; Shock, Septic; Spain; Treatment Outcome | 2012 |
Combinations of cefoxitin plus other β-lactams are synergistic in vitro against community associated methicillin-resistant Staphylococcus aureus.
Topics: beta-Lactams; Cefoxitin; Community-Acquired Infections; Cross Infection; Drug Synergism; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Staphylococcal Infections | 2013 |
Severe community-acquired pneumonia treated with β-lactam-respiratory quinolone vs. β-lactam-macrolide combination.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Macrolides; Male; Middle Aged; Pneumonia; Quinolones; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2013 |
Extended-spectrum beta-lactamases in Enterobacteriaceae: related to age and gender.
Topics: Adult; Age Factors; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Pakistan; Sex Factors | 2002 |
Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Bronchitis, Chronic; Community-Acquired Infections; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lactams; Microbial Sensitivity Tests; Pneumonia, Bacterial | 2002 |
In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Ertapenem; Haemophilus influenzae; Humans; Lactams; Microbial Sensitivity Tests; Moraxella catarrhalis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes | 2002 |
[The clinical significance of broad-spectrum beta-lactamases].
Topics: Bacterial Proteins; Bacterial Typing Techniques; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Europe; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Incidence | 2003 |
Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Topics: Administration, Oral; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Haemophilus influenzae; Macrolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Staphylococcus aureus; Streptococcus pneumoniae | 2003 |
[Epidemiological study on patients with pneumococcal respiratory tract infection in a Japanese health facility during the past year].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Chronic Disease; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Lactams; Male; Middle Aged; Ofloxacin; Pneumococcal Infections; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors | 2001 |
[Comparative study on bacterial eradication rate and clinical efficacy of CDTR, CFPN, and FRPM for treatment of children with otitis media and lower respiratory tract infection due to Streptococcus pneumoniae and Haemophilus influenzae].
Topics: Ampicillin Resistance; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Child; Child, Preschool; Community-Acquired Infections; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Lactams; Otitis Media; Penicillin Resistance; Pneumococcal Infections; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae; Treatment Outcome | 2001 |
Short-course beta-lactam treatment for community-acquired pneumonia.
Topics: beta-Lactam Resistance; beta-Lactams; Community-Acquired Infections; Humans; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Streptococcus pneumoniae | 2004 |
[E. coli: resistance to quinolones and beta-lactams of clinical strains isolated in the Franche-Comté region of France].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Ceftazidime; Cephalothin; Ciprofloxacin; Clavulanic Acid; Community-Acquired Infections; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Utilization; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; France; Genotype; Humans; Male; Middle Aged; Nalidixic Acid; Phenotype; Selection, Genetic; Urinary Tract Infections | 2004 |
Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
Topics: Abdomen; Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Clinical Trials as Topic; Community-Acquired Infections; Ertapenem; Female; Humans; Lactams; Male; Microbial Sensitivity Tests; Middle Aged; Rats | 2004 |
Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Resistance, Bacterial; Haemophilus influenzae; Humans; In Vitro Techniques; Ketolides; Macrolides; Microbial Sensitivity Tests; Multicenter Studies as Topic; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes; United States | 2004 |
Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Drug Therapy, Combination; Enterobacteriaceae; Ertapenem; Female; Haemophilus influenzae; Hospitalization; Humans; Injections, Intravenous; Lactams; Male; Middle Aged; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Streptococcus pneumoniae; Treatment Outcome | 2004 |
Treatment of complicated community-acquired infections with ertapenem, the first Group 1 carbapenem. Introduction.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactams; Carbapenems; Community-Acquired Infections; Drug Resistance, Bacterial; Ertapenem; Humans; Lactams | 2004 |
Ertapanem therapy for community-acquired pneumonia in the elderly.
Topics: Aged; beta-Lactams; Community-Acquired Infections; Ertapenem; Humans; Lactams; Pneumonia | 2004 |
A step forward in the everyday management of adults with community acquired pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Double-Blind Method; Humans; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
[Expanded-spectrum beta-lactamase-producing strains of E. coli: origin, characteristics and incidence in Southern Alicante (Spain) in the period 1999-2003].
Topics: beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Hospitals, General; Hospitals, University; Humans; Incidence; Inpatients; Outpatients; Spain | 2005 |
[Resistance to penicillin and erythromycin of Streptococcus pneumoniae and Streptococcus pyogenes isolated from community-acquired respiratory infections in Spain between 1986-1999 and its relationship with the use of beta-lactams and macrolides].
Topics: beta-Lactams; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Utilization; Erythromycin; Humans; Macrolides; Penicillin Resistance; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Spain; Streptococcal Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 2005 |
Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Pneumococcal; Polymerase Chain Reaction; Respiratory Tract Infections; Streptococcus pneumoniae | 2005 |
Countrywide spread of community- and hospital-acquired extended-spectrum beta-lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Lebanon; Microbial Sensitivity Tests; Polymerase Chain Reaction | 2005 |
MRSA in the community.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Toxins; beta-Lactams; Community-Acquired Infections; Enterotoxins; Female; Humans; Methicillin Resistance; Risk Factors; Shock, Septic; Staphylococcal Infections; Staphylococcus aureus; Superantigens; Vancomycin | 2005 |
Clinical and molecular analysis of extended-spectrum {beta}-lactamase-producing enterobacteria in the community setting.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Plasmids; Polymerase Chain Reaction; Restriction Mapping; Risk Factors; Urinary Tract Infections | 2005 |
[Initial treatment can lighten low-severity community-acquired pneumonia].
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Humans; Pneumonia | 2005 |
Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Synergism; Drug Therapy, Combination; Humans; Macrolides; Middle Aged; Pneumonia, Pneumococcal | 2006 |
The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Hospital Mortality; Humans; Male; Middle Aged; Pneumonia, Bacterial; Retrospective Studies | 2005 |
Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
Topics: beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prevalence; Risk Factors; Urinary Tract Infections | 2006 |
Community-acquired pneumonia in Malaysian patients: addition of macrolide and the use of BTS "curb" index to assess severity.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Female; Humans; Macrolides; Malaysia; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Reproducibility of Results; Severity of Illness Index | 2006 |
Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals, University; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2006 |
Outcome of 8-hour dosing intervals with beta-lactam antibiotics in adult acute bacterial meningitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Administration Schedule; Female; Humans; Male; Meningitis, Bacterial; Meningitis, Listeria; Meningitis, Meningococcal; Meningitis, Pneumococcal; Middle Aged; Retrospective Studies; Treatment Outcome | 2006 |
Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae: Has resistance to antibiotics decreased?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Community-Acquired Infections; Disease Susceptibility; Drug Resistance, Bacterial; Female; Hospital Mortality; Hospitalization; Humans; Incidence; Macrolides; Male; Middle Aged; Pneumonia, Pneumococcal; Prognosis; Prospective Studies; Risk Factors; Spain; Streptococcus pneumoniae; Survival Analysis | 2006 |
Antibiotic treatment of community acquired pneumonia varies widely across Germany.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Germany; Humans; Macrolides; Male; Middle Aged; Multivariate Analysis; Pneumonia, Bacterial; Practice Patterns, Physicians'; Treatment Outcome | 2007 |
Decrease in drug resistance in pneumococcal community-acquired pneumonia.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Pneumococcal Vaccines; Pneumonia, Pneumococcal; Spain; Streptococcus pneumoniae | 2007 |
Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Epidemiologic Methods; Female; Guideline Adherence; Humans; Length of Stay; Macrolides; Male; Middle Aged; Patient Readmission; Pneumonia, Bacterial; Practice Guidelines as Topic; Prognosis; Quinolones; Severity of Illness Index; Spain; Treatment Outcome | 2007 |
Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacteria, Aerobic; beta-Lactams; Child; Child, Preschool; Community-Acquired Infections; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Taiwan | 2007 |
Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
Topics: Adolescent; Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Child; Child, Preschool; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Female; Genotype; Haemophilus Infections; Haemophilus influenzae; Humans; Infant; Infant, Newborn; Japan; Macrolides; Male; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Phylogeny; Pneumococcal Infections; Polymerase Chain Reaction; Respiratory Tract Infections; Sequence Analysis, DNA; Serotyping; Streptococcus pneumoniae | 2007 |
Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Length of Stay; Macrolides; Male; Middle Aged; New York; Pneumonia, Bacterial; Retrospective Studies; Treatment Outcome; Veterans | 2007 |
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Geography; Haemophilus influenzae; Health Surveys; Humans; Moraxella catarrhalis; Penicillin Resistance; Respiratory Tract Infections; Streptococcus pneumoniae; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2007 |
[Atypical pneumonia: are the recommendations evidence-based?].
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Evidence-Based Medicine; Humans; Pneumonia, Bacterial | 2007 |
Trends in prescribing beta-lactam antibiotics for treatment of community-associated methicillin-resistant Staphylococcus aureus infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Community-Acquired Infections; Drug Prescriptions; Female; Health Services Research; Humans; Infant; Infant, Newborn; Male; Methicillin Resistance; Middle Aged; Prevalence; Staphylococcal Infections; Staphylococcus aureus; United States | 2007 |
Activity of ertapenem and other antimicrobials against ESBL-producing enterobacteria isolated from urine in patients from Madrid.
Topics: Adult; Anti-Bacterial Agents; Bacteriuria; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Humans; Male; Membrane Proteins; Microbial Sensitivity Tests; Middle Aged; Outpatient Clinics, Hospital; Spain; Urine | 2007 |
Predictors of mortality among patients with community-onset infection due to extended-spectrum beta-lactamase-producing Escherichia coli in Thailand .
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacteremia; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Case-Control Studies; Community-Acquired Infections; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Multivariate Analysis; Thailand | 2008 |
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; United States | 2008 |
Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006).
Topics: Anti-Bacterial Agents; beta-Lactams; Cephalosporins; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Respiratory Tract Infections; Streptococcus pneumoniae | 2008 |
Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres).
Topics: Acetyltransferases; Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Child; Child, Preschool; Community Health Centers; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Female; France; Humans; Infant; Infant, Newborn; Male; Microbial Sensitivity Tests; Middle Aged; Nucleotidyltransferases; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2008 |
Antibiotic resistance and prevalence of beta-lactamase in Haemophilus influenzae isolates-a surveillance study of patients with respiratory infection in Saudi Arabia.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; beta-Lactamases; beta-Lactams; Chloramphenicol; Community-Acquired Infections; Conjunctiva; Drug Resistance, Microbial; Ear, Middle; Female; Haemophilus influenzae; Humans; Male; Microbial Sensitivity Tests; Nasal Lavage Fluid; Prevalence; Respiratory Tract Infections; Roxithromycin; Saudi Arabia; Serotyping; Sputum; Tetracycline | 2000 |
[Prescription of beta-lactams for community-acquired broncho-pulmonary infections in adults. Observations in the hospital environment].
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Costs; Drug Prescriptions; Female; Hospitalization; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Prospective Studies; Respiratory Tract Infections | 2000 |
Ertapenem (Invanz)--a new parenteral carbapenem.
Topics: Anti-Bacterial Agents; beta-Lactams; Clinical Trials as Topic; Community-Acquired Infections; Dose-Response Relationship, Drug; Ertapenem; Gram-Negative Bacterial Infections; Humans; Infusions, Parenteral; Injections, Intramuscular; Injections, Intravenous; Lactams; Pneumonia; Urinary Tract Infections | 2002 |
Pharmacokinetics and pharmacodynamics of oral beta-lactam antibiotics as a two-dimensional approach to their efficacy.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Drug Administration Schedule; Drug Resistance, Bacterial; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Models, Biological; Moraxella catarrhalis; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes; Time Factors | 2002 |